 | Health Care & Policy |  |  | | - Avastin works against glioblastoma in study, Roche says
Roche Holding said cancer treatment Avastin, by subsidiary Genentech, significantly extended progression-free survival of glioblastoma patients in a late-stage trial. "This study showed that people with glioblastoma, a particularly devastating and aggressive cancer without many treatment options, lived significantly longer without their disease worsening when Avastin was added to radiation and temozolomide chemotherapy," the drugmaker said. Information on final overall survival is expected next year. Reuters (8/10)       - Pharma, iPhones and patent protection
 Weaker patent protections may make sense in the realm of consumer goods, but biotechnology companies need a strong intellectual property system to thrive and innovate, writes Christoph Westphal. The court battle between Apple and Samsung has fueled criticism of a system that allows patents for minimal changes to existing technology, but that doesn't apply in the world of pharmaceuticals, Westphal writes. The Boston Globe (tiered subscription model) (8/11) - S*BIO licenses pracinostat to MEI Pharma
MEI Pharma obtained exclusive, worldwide rights to S*BIO's pracinostat, an experimental oral histone deacetylase inhibitor that has demonstrated single-agent activity against advanced hematologic diseases. The deal entitles S*BIO to $500,000 worth of MEI common stock plus up to $75.2 million in milestone fees. The agreement is expected to be finalized this month. The Pharma Letter (U.K.) (subscription required) (8/8) | Company & Financial News | | | | - NASA taps Tissue Genesis for stem cell research contract
Tissue Genesis has been tapped by the NASA to receive a $2 million contract for further research on the reactions of human stem cells in space. A team at the biotech firm has developed a bio-reactor with a cold and a hot chamber needed to regenerate as well as grow human stem cells. The technology can be used by scientists around the world to send stem cell samples to outer space. KHNL-TV/KGMB-TV (Honolulu) (8/9) | Drug Development & Manufacture Basic Training | | | | - How to choose between allogeneic and autologous stem cell therapy
Rapid progress is being made in stem cell research and, looking ahead, most cell-based therapies are likely to be either autologous, where stem cells are harvested from a patient and culture expanded ex vivo to large quantities over many weeks and then returned to the patient; or allogeneic, where culture expanded stem-cells originating from a single donor provide treatments to large numbers of patients. The author discusses the pros and cons of each. Get more free content like this by subscribing to BioPharm International. BioPharm International (7/2012)
| Food & Agriculture | | | | - Transgenic carrot containing TB vaccine developed in Kazakhstan
Scientists at the National Biotechnology Center in Kazakhstan have developed carrots with the tuberculosis vaccine, said Director General Yerlan Ramankulov. Laboratory tests in animals showed that the carrots improve tuberculosis immunity. "Of course, it is too early to enter the pharmaceutics market with the product. We still need to prove therapeutic effect and this requires significant investments," Ramankulov said. Tengri News (Kazakhstan) (8/7) | Hot Topics | | | | Top five news stories selected by BIO SmartBrief readers in the past week. - Results based on number of times each story was clicked by readers.
| Industrial & Environmental | | | | - Eco Ventures granted local permits to produce and sell biofuels
Eco Ventures Group has obtained local permits for the production and sale of biofuel at its headquarters in Groveland, Fla. Construction of the biofuel facility, with a capacity of 3.6 million gallons per year, is expected to be completed in the fourth quarter. If state and federal permits come through, the plant could start commercial production early next year. The Daily Commercial (Fla.) (8/12) | News from BIO | | | | - BIOtechNOW
BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the e-newsletter.
| SmartQuote | | | |  | It takes a very deep-rooted opinion to survive unexpressed."
--Jean Rostand,
French biologist and philosopher  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Friday, August 10, 2012
- Thursday, August 09, 2012
- Wednesday, August 08, 2012
- Tuesday, August 07, 2012
- Monday, August 06, 2012
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2012 SmartBrief, Inc.® Legal Information |
|
1 comment:
Nice Article! Thanks for sharing with us.
Diabetic Products
Post a Comment